Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
K. Slimane
Observed names:
K Slimane,
Karah K. Slimane
Institutions:
Novartis (Switzerland),
Novartis (France)
Observed institutions:
Novartis (Switzerland),
The University of Texas MD Anderson Cancer Center,
École Nationale Vétérinaire d'Alfort,
Institut Gustave Roussy,
Novartis (France),
Hôpital Saint-Louis,
Université Paris Descartes,
Institut Curie
show all 8
OpenAlex ID:
A5110335685
Risk factors for brain relapse in patients with metastatic breast cancer
2004
·
K. Slimane
, F. Andre
, et al.
·
Annals of Oncology
·
173
PDF
Rupture of an abdominal aortic aneurysm after endovascular graft placement and aneurysm size reduction
1998
·
Yves S. Alimi
, Nabil Chakfe
, et al.
·
Journal of Vascular Surgery
·
157
PDF
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
2009
·
R. de Crevoisier
, K. Slimane
, et al.
·
Annals of Oncology
·
37
PDF
Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma
2014
·
C D Santos
, A Tijeras-Raballand
, et al.
·
British Journal of Cancer
·
20
PDF
mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response
2015
·
M. Lamuraglia
, S. Raslan
, et al.
·
European Radiology
·
14
238P BOLERO-5: A phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER+/HER2- advanced breast cancer
2021
·
Z. Shao
, L. Cai
, et al.
·
Annals of Oncology
·
10
PDF
Open-Label Phase II Trial of First-Line Everolimus Monotherapy in Patients with Advanced Papillary Renal Cell Carcinoma: Raptor Interim Analysis
2012
·
B. Escudier
, S. Bracarda
, et al.
·
Annals of Oncology
·
7
PDF
Open-label phase II trial of everolimus monotherapy in treatment-naive patients with advanced papillary renal cell carcinoma.
2010
·
S. Caglio
, K. Slimane
, et al.
·
Journal of Clinical Oncology
·
6
Preclinical Rational, Safety, and Preliminary Efficacy Results of Weekly Everolimus, Carboplatin and Paclitaxel as An Induction Therapy for Patients with Unresectable Locally Advanced Head & Neck Squamous Cell Carcinoma (CAPRA): A GERCOR-IRC Phase I/II Study
2012
·
S. Faivre
, C. Dreyer
, et al.
·
Annals of Oncology
·
4
PDF
Multicentric phase II clinical trial evaluating the role of everolimus (RAD001) in endemic or classic Kaposi’s sarcoma (C06-46).
2011
·
R. Porcher
, D. Kerob
, et al.
·
Journal of Clinical Oncology
·
3
Abstract P6-04-14: Targeting the PI3K/mTOR pathway in patient-derived xenograft models of endocrine resistant luminal breast cancer
2012
·
PH Cottu
, T Bagarre
, et al.
·
Cancer Research
·
2
333 Preclinical Testing of Everolimus in Combination with Standard Endocrine Treatments in Hormone-resistant Patient-derived Luminal Breast Cancer Xenografts
2012
·
E. Marangoni
, T. Bagarre
, et al.
·
European Journal of Cancer
·
2
Everolimus as first-line or after cytokine therapy in patients with metastatic recurrent and/or unresectable renal cell carcinoma (RCC) (EVERMORE)
2018
·
A.M. Abdel Hakim
, Y. Nouira
, et al.
·
Annals of Oncology
·
1
Evesor the First Model-Based Multi-Parameter Phase 1 Trial Meant to Optimize the Benefit/Toxicity Ratio of Everolimus and Sorafenib Association: Preliminary Pd Outcomes
2014
·
M.A. Mohamed
, E. Henin
, et al.
·
Annals of Oncology
·
1
Interest of CHOI and modified CHOI criterion for evaluation of metastatic renal cell carcinomas (mRCC) patients treated with Everolimus
2011
·
O. Lucidarme
, M. Lamuraglia
, et al.
·
Cancer Imaging
·
1
Open-label phase II trial of everolimus monotherapy for patients with advanced papillary renal cell cancer (RAPTOR): rationale and design
2009
·
S. Caglio
, A. Sundlov
, et al.
·
European Journal of Cancer Supplements
·
1
Early undetectable serum PSA is an independent predictive factor of progression-free survival (PFS) and bone metastases in patients with localized prostate cancer treated by androgen deprivation and radiotherapy
2004
·
K. Fizazi
, K. Slimane
, et al.
·
Journal of Clinical Oncology
·
1
Prognostic role of serum Ca 15–3 and circumstances of diagnostic in advanced breast cancer: Data from a prospective randomized trial
2004
·
R. Rouzier
, K. Slimane
, et al.
·
Journal of Clinical Oncology
·
1
Real-world assessment of clinical effectiveness and safety of pazopanib in patients with advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: A prospective, observational study (PARACHUTE)
2019
·
R. Kanesvaran
, B. Biswas
, et al.
·
Annals of Oncology
Prospective Observational Study on the Evaluation of Everolimus Adverse Events (Aes) in Metastatic Renal Cell Carcinoma (Mrcc) After First-Line Anti-Vegf Therapy. the French Afinite Study
2014
·
F. Joly Lobbedez
, J. Eymard
, et al.
·
Annals of Oncology
PDF
Abstract P5-09-07: Identification of resistance-specific gene expression signatures in a breast cancer patient-derived xenograft with acquired resistance to different endocrine therapies
2013
·
PH Cottu
, I Bièche
, et al.
·
Cancer Research
Phase I Trial of RAD001 (Everolimus) in Combination with Radiotherapy in Non-Small Cell Lung Cancer
2013
·
E. Deutsch
, C. Lepechoux
, et al.
·
Annals of Oncology
Efficacy and Safety of Sequential Usage of Everolimus in Patients with Metastatic Renal Cell Carcinoma (MRCC) Previously Treated with Bevacizumab +/- Interferon (INF) Therapy. Results from the European Avator Retrospective Study
2012
·
A. Vuillemin
, C. Theodore
, et al.
·
Annals of Oncology
PDF
POSTER DISCUSSION Interest of CHOI and Modified CHOI Criterion for Evaluation of Metastatic Renal Cell Carcinomas (mRCC) Patients Treated With Everolimus
2011
·
M. Lamuraqlia
, S. Oudard
, et al.
·
European Journal of Cancer
Impact of PSA decrease at the end of radiotherapy for localized prostate cancer on clinical recurrence and specific cause survival
2007
·
R. de Crevoisier
, T. Messai
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
29
Citation count:
441
H-index:
7
I10-index:
6
Year
Topic
Type